Skip to main content
. 2020 Dec 15;23(3):791–799. doi: 10.1111/dom.14268

FIGURE 1.

FIGURE 1

Modelled treatment pathways. Patients are on dual therapy at the beginning of the simulation model. CVD, cardiovascular disease; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; SGLT‐2i, sodium‐glucose co‐transporter‐2 inhibitor; T2D, type 2 diabetes